Taysha Gene Therapies
Leigh Fuller is an accomplished quality executive with extensive experience in the pharmaceutical and gene therapy sectors. Currently serving as Executive Director of Quality at Taysha Gene Therapies since March 2021, Leigh oversees strategic development and quality management across GMP, GCP, GVP, and GLP requirements. Prior to this role, Leigh held key positions at bluebird bio, including Director of Quality Engineering and Quality Systems, and Associate Director of Quality Assurance. Leigh's earlier career includes significant roles at Mallinckrodt Pharmaceuticals, Barry-Wehmiller Design Group, Day & Zimmermann, and Pharm Tech Inc., focusing on quality operations, compliance, validation, and engineering. Leigh holds a Bachelor's degree in Pharmaceutical Sciences from Campbell University.
This person is not in any teams
This person is not in any offices
Taysha Gene Therapies
Taysha Gene Therapies is on a mission to eradicate severe and life-threatening monogenic CNS disease. With a singular focus on developing curative medicines, they hope to rapidly translate their treatments from bench to bedside.